drugset / Trial / NCT06992024

Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer

NCT06992024 ↗

NaSingle-groupOpen-labelTreatment

Summary

There are several basic findings in the previous studies: The levels of renin and aldosterone in the blood of cancer patients vary greatly among individuals, and the baseline levels of some patients are relatively higher than others; The elevated levels of renin and aldosterone in the blood are positively correlated with the higher malignancy, drug resistance and progression of gastric cancer; Electroacupuncture stimulation of relevant acupoints can effectively down-regulate the levels of renin and aldosterone in the blood; Electroacupuncture stimulation of relevant acupoints can effectively activate the function of the immune system. Based on these findings, the present clinical trial aim to evaluated the efficacy and safety of electroacupuncture combined with chemotherapy and PD-1 Antibody for the treatment of specific type of gastric cancer.

Timeline

Start
2025-04-01
Primary completion
2026-03-31
Completion
2026-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 125 mg/m2 —

Indications

No indication recorded.